APR 03, 2018 8:27 PM PDT

Two-Drug Strategy for Non-Small Cell Lung Cancer (NSCLC)

WRITTEN BY: Nouran Amin

According to the National Cancer Institute, lung cancer is the most common cause of cancer death for both men and women in the U.S. More specifically, non-small cell lung cancer (NSCLC) encompasses 85% of all lung cancers.

Investigators seeking new treatment options for patients of lung cancer have found a combination of drugs that are effective for NSCLC specifically. These drugs target epidermal growth factor receptor (EGFR) and tumor necrosis factor (TNF), the targeting works to effectively inhibit the cancer from using TNF as way to escape and allowing the cancer to be sensitive to the EGFR treatment.

"There has been a tremendous effort over the past several years to block EGFR as a treatment for lung cancer, but this therapy only works in a small subset of patients. The cancer fights back with a bypass pathway," explains lead researcher Dr. Amyn Habib with the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern as well as a staff physician at the Dallas Veterans Affairs Medical Center. "Blocking both of these proteins could be a treatment that is beneficial for the majority of lung cancer patients.” These research findings stem from the same combination of drug treatments that were found to be successful in a glioblastoma mouse model.Bottom Rows: Tumors treated w/ two-drug strategy. Top Rows: Tumors left untreated or w/ a single treatment. Credit: UT Southwestern via Science Daily

Furthermore, these anti-EGFR/TNF two-strategy drugs were found to be well tolerated and with few side effects which was because they worked to target specific molecules within cancer cells. Thus, anti-EGFR/TNF drugs are more advantageous than traditional chemotherapeutic treatments which have unpleasant side-effects on a patient.

Investigators will continue their research for a phase 2 clinical trial of using the two-drug strategy; which has already been approved by the FDA. The prospective clinical studies are being planned to test the two-drug treatment in lung cancer patients as well as glioblastomas. "If this strategy is effective, then it might be broadly applicable not only against lung cancer but also against other cancers that express EGFR, which include brain, colon, and head and neck cancers," says lead clinical studies leader Dr. Gerber, an Associate Professor of Internal Medicine and Clinical Sciences.

Until recently, EGFR inhibitors were studied to be effective at treating a small percentage of non-small cell lung cancers that have a variant form of EGFR. However, with two-drug strategy, treatment could be effective for all forms of non-small cell lung cancers.

The research was published in the Journal of Clinical Investigation.

Source: Journal of Clinical Investigation, Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 25, 2019
Technology
NOV 25, 2019
How artificial intelligence (AI) is improving immunotherapy
Researchers at Case Western Reserve University’s digital imaging lab are pioneering the use of Artificial Intelligence (AI) to predict the efficacy o...
DEC 09, 2019
Drug Discovery & Development
DEC 09, 2019
MagLev: Telling Drugs Apart
Likely, a suspicious powder will be composed of illicit drugs but nothing is certain until confirmation. To do so, analysis must be quick and efficient and...
DEC 18, 2019
Drug Discovery & Development
DEC 18, 2019
Stroke Drug Enhances Stem Cell Therapies for Spinal Cord Injuries
Using rat models of spinal cord injuries, Yasuhiro Shiga, MD, PhD, thought treating them with stem cell therapy would point to nowhere but the nature of re...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
A New Drug Target for Substance Abuse
Research carried out by the University of Minnesota Medical School indicates a new drug target for treating a drug addiction. Researchers note that the dru...
FEB 06, 2020
Drug Discovery & Development
FEB 06, 2020
Potential Cure for Coronavirus Found in Thailand
Doctors in Thailand have successfully treated people affected by the coronavirus via a new drug cocktail made out of antiviral, flu and HIV medication. Alt...
FEB 10, 2020
Cardiology
FEB 10, 2020
Blocking Problem Protein Shows Promise for Preventing Heart Attacks
Over time, atherosclerosis, a disease that causes fatty plaques to build up in the arteries, limits the flow of oxygen-rich blood to vital organs. Often le...
Loading Comments...